Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company. At Catabasis Pharmaceuticals, the company’s mission is to bring hope and life-changing therapies to patients and their families. Their lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy.
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| - Catabasis Pharmaceuticals (en)
|
rdfs:comment
| - Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company. At Catabasis Pharmaceuticals, the company’s mission is to bring hope and life-changing therapies to patients and their families. Their lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. (en)
|
foaf:name
| - Catabasis Pharmaceuticals (en)
|
foaf:homepage
| |
name
| - Catabasis Pharmaceuticals (en)
|
foaf:depiction
| |
location
| |
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
Link from a Wikipage to an external page
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
thumbnail
| |
homepage
| |
industry
| |
key people
| - Jill C. Milne, Ph.D.
Joanne M. Donovan, M.D., Ph.D.
Andrew Nichols, Ph.D. , Deirdre A. Cunnane (en)
|
location
| |
logo
| |
num employees
| |
products
| - Orally-delivered pharmaceuticals (en)
|
traded as
| - Russell Microcap Index component (en)
- NASDAQ:CATB (en)
|
type
| |
has abstract
| - Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company. At Catabasis Pharmaceuticals, the company’s mission is to bring hope and life-changing therapies to patients and their families. Their lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. In Catabasis’s Phase 2 MoveDMD clinical trial and open-label extension, edasalonexent was shown to preserve muscle function as assessed by the North Star Ambulatory Assessment and Timed Function Tests compared with the rate of change during an off-treatment control period. It also showed a significant decrease in CRP, muscle enzymes including CK, and decrease in heart rate to age-normative values [1]. (en)
|
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
founding year
| |
number of employees
| |
industry
| |
type
| |
foaf:isPrimaryTopicOf
| |
is Link from a Wikipage to another Wikipage
of | |
is foaf:primaryTopic
of | |